Abstract
The acquired haemophilia is caused by formation of autoantibodies which are most frequently directed against factor VIII (FVIII). This disease associated with considerable morbidity as well as mortality occurs preferentially in the elderly. The antibodies lead to a loss of FVIII activity resulting in bleeds especially of soft or subcutaneous tissue or in muscles. aPTT prolongation and the reduction of the factor activity are of diagnostic importance. However, with respect to bleeding tendency basal activity and inhibitor titre are less meaningful than in inherited haemophilia complicated by inhibitor formation. Therapy is subdivided into treatment of acute bleeds and long-term eradication of the inhibitor. Administration of recombinant FVIIa, high dosed FVIII or activated prothrombin complex concentrates represent approved treatment options of bleeding episodes. Immunosuppressive agents occasionally combined with FVIII administration or immunoadsorption may lead to long-term inhibitor eradication. As CD4(+) T cells as well as anti-idiotypic antibodies appear to be increasingly pathogenetically meaningful new immunomodulating agents might improve the treatment of acquired haemophilia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
